These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12787259)

  • 1. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
    Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
    Reches A; Jiang D; Fahn S
    Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor.
    Bonifácio MJ; Vieira-Coelho MA; Soares-da-Silva P
    Eur J Pharmacol; 2003 Jan; 460(2-3):163-70. PubMed ID: 12559377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
    Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
    Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A; Zürcher G; Da Prada M
    Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.
    Learmonth DA; Vieira-Coelho MA; Benes J; Alves PC; Borges N; Freitas AP; da-Silva PS
    J Med Chem; 2002 Jan; 45(3):685-95. PubMed ID: 11806720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
    Zürcher G; Colzi A; Da Prada M
    J Neural Transm Suppl; 1990; 32():375-80. PubMed ID: 2089102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
    Reches A; Jiang D; Fahn S
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
    Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
    Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.